Correlation Between Annaly Capital and CRISPR Therapeutics

Can any of the company-specific risk be diversified away by investing in both Annaly Capital and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Annaly Capital and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Annaly Capital Management, and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Annaly Capital and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Annaly Capital with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Annaly Capital and CRISPR Therapeutics.

Diversification Opportunities for Annaly Capital and CRISPR Therapeutics

-0.02

Correlation Coefficient

Annaly Capital  CRISPR Therapeutics

Good diversification

The 3 months correlation between Annaly and CRISPR is -0.02. Overlapping area represents the amount of risk that can be diversified away by holding Annaly Capital Management, and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Annaly Capital is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Annaly Capital Management, are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Annaly Capital i.e., Annaly Capital and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Annaly Capital and CRISPR Therapeutics

Assuming the 90 days trading horizon Annaly Capital Management, is expected to generate 0.6 times more return on investment than CRISPR Therapeutics. However, Annaly Capital Management, is 1.65 times less risky than CRISPR Therapeutics. It trades about 0.1 of its potential returns per unit of risk. CRISPR Therapeutics AG is currently generating about -0.01 per unit of risk. If you would invest  10,469  in Annaly Capital Management, on October 4, 2024 and sell it today you would earn a total of  858.00  from holding Annaly Capital Management, or generate 8.2% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	81.36%
Values	Daily Returns

Annaly Capital Management,  vs.  CRISPR Therapeutics AG

Annaly Capital Manag

Risk-Adjusted Performance

0 of 100

OK

Over the last 90 days Annaly Capital Management, has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat weak essential indicators, Annaly Capital may actually be approaching a critical reversion point that can send shares even higher in February 2025.

CRISPR Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Annaly Capital and CRISPR Therapeutics

The main advantage of trading using opposite Annaly Capital and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Annaly Capital position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.

The idea behind Annaly Capital Management, and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.